Application of Ertapenem in Pediatric Emergency Antimicrobial Therapy
10.11969/j.issn.1673-548X.2025.07.017
- VernacularTitle:厄他培南在急诊儿童抗感染治疗中的应用研究
- Author:
Yanning QU
1
;
Zhuyan DUAN
1
;
Mengyi SHENG
1
Author Information
1. 100020 北京,首都医科大学附属首都儿童医学中心
- Publication Type:Journal Article
- Keywords:
Ertapenem;
Pediatric emergency;
Infectious diseases;
Retrospective study
- From:
Journal of Medical Research
2025;54(7):91-95,144
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the clinical indications,efficacy,and safety of ertapenem for pediatric emergency infectious disea-ses,and to analyze factors guiding its use to inform rational medication choices.Methods A retrospective cohort study was performed on 538 pediatric patients with bacterial infections treated with ertapenem in the Emergency Department of the Capital Institute of Pediatrics from January to December 2023.Patient demographics,diagnoses,infection types,and treatment data were collected.Univariate and multivariate logistic regression analyses were used to identify risk factors for hospitalization.Results Ertapenem was broadly applied across all pediatric age groups,primarily for pneumonia(25.8％),suppurative tonsillitis(18.4％),and bronchitis(14.7％).Some patients with relatively common infections switched to ertapenem due to severe clinical presentations,poor response to initial antibiotics,or cephalosporin allergy.Key indications included cephalosporin allergy(48.4％),failure of prior antibiotics(37.2％),and moderate to severe infections(12.5％).Overall,80.9％of patients improved clinically;median time to defervescence was 2days,median time for inflammatory marker normalization was 4days,and median total treatment duration was 5days.The incidence of adverse events was 9.5％,mainly mild to moderate gastrointestinal disturbances(5.2％diarrhea,2.2％nausea/vomiting).Multivariate analysis identified pneumo-nia,lymphadenitis,urinary tract infection,and underlying diseases as independent risk factors for hospitalization.Conclusion Ertapen-em demonstrates good efficacy and a favorable safety profile in pediatric emergency infectious diseases,particularly for moderate to severe infections,cephalosporin allergy,and cases unresponsive to initial antibiotic therapy.
